

# Call for Papers for the 33<sup>rd</sup> Joint Annual Conference of Biomedical Science – Submission Guidelines

## Key Points Regarding Submissions:

1. Submission deadline: **17:00 p.m. on December 31, 2017.**
2. Associations: To submit a paper, please select one of the following nine associations: The Chinese of Society of Cell and Molecular Biology / The Taiwan Society of Biochemistry and Molecular Biology / Toxicology Society of Taiwan / Chinese Association for Clinical Biochemistry / The Chinese Physiological Society / the Pharmacological Society of Taiwan /The Association of Anatomists of the Republic of China / The Chinese Society of Immunology / Taiwanese Society for Molecular Imaging
3. For all submissions, **the abstract must be submitted online.** The abstracts must be correctly written in accordance with the relevant regulations and the specified format.
4. Please note that the submission abstract content published in the Conference Handbook will be based on the data that you submit; all authors are responsible for ensuring the accuracy and completeness of the information that they submit.
5. Abstracts must be written in English. With the exception of prepositions, the first letter of every word in the abstract title should be capitalized. Please submit abstracts in Microsoft Word format (Word 2007 or later). Abstracts must not exceed 2500 characters (including space) in length.  
For more details, see [Conference Submission Rules and Format](#) and [Submission Abstract Form](#)
6. A given submission may not be submitted under the auspices of more than one association.
7. All submissions received by post or fax, or in any other manner different from that specified by the Conference regulations, will be rejected (in such cases, submissions will not be returned).
8. When a submission has been received, it will undergo review by the Conference organizers. Those submissions that successfully pass review will be accepted for inclusion in the Conference, and will be assigned a Paper Number and a Presentation Format. Authors are requested to check for themselves whether a submission has been accepted by visiting the relevant website after **January 31, 2018** to check the status of their submission.
9. Arrangements will be made for all accepted papers to be included in a poster session.
10. If your submission is accepted, you will receive an acceptance confirmation e-mail.
11. Please ensure that your submission conforms to the format specified by the Conference organizers. If your submission does not conform to the required format, the organizers reserve the right to reject the submission, and to ask you to re-submit it in conformity with the specified format.

Please ensure that poster presentations conform to the following requirements, to help ensure that the Conference proceeds as smoothly as possible.

1. Poster presentations will be held on the First Floor, Second Floor and Third Floor of the Conference venue. Please check the announcements on the Conference website for more detailed information.
2. Timetable for poster presentations: Note that the time is subject to be changed yearly. **Please read the on-line timetable in late February.**

3/24/2018

	<b>Period for posting up presentation posters</b>	<b>Period for display of presentation posters</b>	<b>Period in which the author should be present to discuss the presentation</b>	<b>Time by which the poster should be taken down</b>
Morning group	8:30 - 9:00	9:00 - 12:00	11:15 - 12:00	By 12:10
Afternoon group	12:30 - 13:00	13:00 - 17:00	13:00 - 13:45	By 17:10

3/25/2018

	<b>Period for posting up presentation posters</b>	<b>Period for display of presentation posters</b>	<b>Period in which the author should be present to discuss the presentation</b>	<b>Time by which the poster should be taken down</b>
Morning group	8:30 ~ 9:00	9:00~12:30	11:30~12:30	by 12:40
Afternoon group	12:50~13:30	13:30~17:00	13:30~14:30	by 17:10

3. The Conference organizers will provide boards on which presentation posters can be displayed (**the boards will be upright, and will be approximately 150 cm in height and 90 cm in width**), as well as labels and double-sided adhesive tape. The Conference organizers will mark the Paper Number on each board; authors are asked to make sure that they post up their presentation poster on the correct board.
4. The graphics and text displayed on the presentation poster should be large enough to be clearly visible at a distance of 1 meter.
5. During the time period in which the author is expected to be present to discuss the poster presentation, at least one of the authors should be present near the

presentation board, wearing their name tag, to discuss the content of the presentation with other Conference participants.

Contact us: Conference assistants: [cscmb.tw@gmail.com](mailto:cscmb.tw@gmail.com)

[Attachment 1]

## 33<sup>rd</sup> Joint Annual Conference of Biomedical Science

### Conference Submission Rules and Format

1. Submission deadline: **17:00 p.m. on December 31, 2017**. All submissions received after the deadline will be rejected.
2. Papers that have already been published elsewhere will not be accepted.
3. Language: All submissions must be written in English.
4. Font, text size and spacing:  
Text must be in English, in Times New Roman font, with a text size of 12 points.  
Spacing: Line spacing should be set to At Least 12 points. Where the format requires that text be kept within borders, make sure that text is kept within the correct field and does not extend beyond the borders. The first letter of each major word in a title must be capitalized.
5. Abstract length: Abstracts must not exceed 2500 characters (including space) in length, and must also not exceed one page in length. Abstracts that do not conform to these requirements will be rejected.
6. File format: All submissions should be saved in Microsoft Word format (Word 2007 or later) and sent as an attachment. The format to be used for file names is as follows:  
**2018 Society name-first Author name.docx** ( Example: **2018Biochemistry-John.docx** )
7. How to make a submission:
  - (1) Download the submission forms (Attachment 1 and Attachment 2).
  - (2) Fill out the required submission information (Attachment 2) in detail.
  - (3) Send the abstract online
  - (4) If your submission is accepted, you will receive an acceptance confirmation e-mail.
8. **Abstracts must follow the following format:**

1. Title →	<b><i>Xist</i> reduction in breast cancer upregulates AKT phosphorylation via HDAC3-mediated repression of PHLPP1 expression</b>
2. Authors' names →	<u>Yen-Sung Huang</u> <sup>1</sup> , Che-Chang Chang <sup>2</sup> , Szu-Shuo Lee <sup>3</sup> , Yuh-Shan Jou <sup>1,3</sup> , Hsiu-Ming Shih <sup>*1,2,3</sup>
3. Names of the institutions to which the authors are attached →	<sup>1</sup> Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan <sup>2</sup> Graduate Institute of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan <sup>3</sup> Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan
4. Abstract content → (Paragraph breaks may not be used. The text presented on the right is given as an example of the style to be followed.)	Long noncoding RNAs (lncRNAs) dysregulated in cancer potentially play oncogenic or tumor-suppressive roles. While the X inactivate-specific transcript ( <i>Xist</i> ) lncRNA is important for X-chromosome inactivation in female cells, very little is known about the role of <i>Xist</i> in human breast cancer in modulating cellular pathway(s). Here, we show that <i>Xist</i> expression is significantly reduced in breast tumor samples and cancer cell lines. <i>Xist</i> knockdown or overexpression resulted in increased or decreased levels, respectively, of AKT phosphorylation and cell viability. Further studies revealed an inverse correlation between <i>Xist</i> and phospho-AKT levels in breast cancer samples. Additionally, <i>Xist</i> knockdown-elicited

increase of cell viability was attenuated by AKT inhibitor. These results suggest that *Xist* negatively regulates cell viability via inhibition of AKT activation. Interestingly, decreased *Xist* expression in breast cancer samples was associated with reduced levels of *Jpx* RNA, an lncRNA that positively regulates *Xist* promoter activity. Accordingly, *Jpx* knockdown enhanced AKT activation and cell viability. We also demonstrate that knockdown of *Xist* or SPEN, an intermediary protein to link *Xist*, SMRT co-repressor and HDAC3 complexes for X-chromosome inactivation, decreased expression of PHLPP1, a phosphatase to remove AKT phosphorylation, via increased HDAC3 recruitment to the PHLPP1 promoter, correlating with increased AKT phosphorylation. Our findings elucidate the tumor suppressor role of *Xist* in breast cancer and provide the molecular basis of *Xist* in downregulating AKT activation.

**(Please fill out the Submission Abstract Form on the next page. Once you have filled out the Form and saved it as a Microsoft Word file, e-mail the file to make your submission)**

33<sup>rd</sup> Joint Annual Conference of Biomedical Science

**Submission Abstract Form (original)**

**Association under whose auspices the submission is made (please select one only):**

The Chinese of Society of Cell and Molecular Biology / The Taiwan Society of Biochemistry and Molecular Biology / Toxicology Society of Taiwan / Chinese Association for Clinical Biochemistry / The Chinese Physiological Society / the Pharmacological Society of Taiwan /The Association of Anatomists of the Republic of China / The Chinese Society of Immunology / Taiwanese Society for Molecular Imaging

**Corresponding author :**

**Passport Number / ARC Number:**

**Tel:**

**Mobile:**

**E-mail:**

**Address:**

**Association:**

**Academic title:**

**Employer:**

**Position held:**